SG11201804050QA - A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic - Google Patents

A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic

Info

Publication number
SG11201804050QA
SG11201804050QA SG11201804050QA SG11201804050QA SG11201804050QA SG 11201804050Q A SG11201804050Q A SG 11201804050QA SG 11201804050Q A SG11201804050Q A SG 11201804050QA SG 11201804050Q A SG11201804050Q A SG 11201804050QA SG 11201804050Q A SG11201804050Q A SG 11201804050QA
Authority
SG
Singapore
Prior art keywords
international
parma
corticosteroid
dry powder
pct
Prior art date
Application number
SG11201804050QA
Other languages
English (en)
Inventor
Claudio Cafiero
Leonardo Ortenzi
Francesca Schiaretti
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54548062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201804050Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of SG11201804050QA publication Critical patent/SG11201804050QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
SG11201804050QA 2015-11-16 2016-11-14 A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic SG11201804050QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15194660 2015-11-16
PCT/EP2016/077558 WO2017085004A1 (fr) 2015-11-16 2016-11-14 Procédé pour préparer une formulation de poudre sèche comprenant un anticholinergique, un corticostéroïde et un bêta-adrénergique

Publications (1)

Publication Number Publication Date
SG11201804050QA true SG11201804050QA (en) 2018-06-28

Family

ID=54548062

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201804050QA SG11201804050QA (en) 2015-11-16 2016-11-14 A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
SG10201912093YA SG10201912093YA (en) 2015-11-16 2016-11-14 A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201912093YA SG10201912093YA (en) 2015-11-16 2016-11-14 A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic

Country Status (36)

Country Link
US (4) US10086004B2 (fr)
EP (3) EP3628331B1 (fr)
JP (1) JP6963548B2 (fr)
KR (1) KR20180082443A (fr)
CN (1) CN108289962B (fr)
AR (1) AR106688A1 (fr)
AU (1) AU2016356858B2 (fr)
CA (1) CA3005290A1 (fr)
CL (1) CL2018001298A1 (fr)
CO (1) CO2018005141A2 (fr)
CY (3) CY1123042T1 (fr)
DK (3) DK3620176T3 (fr)
EA (1) EA037716B1 (fr)
ES (3) ES2895687T3 (fr)
GE (1) GEP20207157B (fr)
HR (3) HRP20211598T1 (fr)
HU (3) HUE056260T2 (fr)
IL (1) IL259329B (fr)
LT (3) LT3377108T (fr)
MA (3) MA50487B1 (fr)
MD (3) MD3628331T2 (fr)
ME (1) ME03778B (fr)
MX (1) MX2018005977A (fr)
MY (1) MY186229A (fr)
PE (1) PE20181488A1 (fr)
PH (1) PH12018501022B1 (fr)
PL (3) PL3628331T3 (fr)
PT (3) PT3377108T (fr)
RS (3) RS60171B1 (fr)
SA (1) SA518391570B1 (fr)
SG (2) SG11201804050QA (fr)
SI (3) SI3628331T1 (fr)
TW (1) TWI731891B (fr)
UA (1) UA125019C2 (fr)
WO (1) WO2017085004A1 (fr)
ZA (1) ZA201803168B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019012931A (es) 2017-05-11 2020-01-20 Chiesi Farm Spa Proceso para preparar una formulacion de polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico.
ES2882153T3 (es) * 2017-05-11 2021-12-01 Chiesi Farm Spa Un proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un betaadrenérgico
US11433063B1 (en) 2019-03-12 2022-09-06 Belhaven Biopharma, Inc. Intranasal composition of pharmaceutical countermeasures for chemical warfare nerve agents and accidental exposure to organophosphate pesticides
EP3947338A4 (fr) * 2019-03-27 2023-01-04 Kemin Industries, Inc. Procédés de préparation de carboxylates métalliques dans une réaction monotope
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
CN116194087A (zh) * 2020-01-15 2023-05-30 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法
WO2022045995A1 (fr) * 2020-08-28 2022-03-03 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Procédé de préparation de compositions de poudre sèche pour inhalation
US20220304894A1 (en) * 2021-03-24 2022-09-29 Cmpd Licensing, Llc Drug powderization within vials
WO2023117967A1 (fr) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Formulations en poudre sèche remplies dans un inhalateur présentant une résistance à l'humidité améliorée

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
EP1386630B1 (fr) 2002-07-31 2006-05-17 CHIESI FARMACEUTICI S.p.A. Inhalateur de poudre
GEP20156311B (en) * 2009-12-23 2015-07-10 Chiesi Farma Spa Combination therapy for copd
CA2893627C (fr) * 2012-12-06 2021-09-14 Chiesi Farmaceutici S.P.A. Composes ayant une activite antagoniste du recepteur muscarinique et agoniste du recepteur beta2 adrenergique
HUE037944T2 (hu) * 2012-12-06 2018-09-28 Chiesi Farm Spa Muszkarin receptor antagonista és béta2 adrenerg receptor agonista akitvitással rendelkezõ vegyületek
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
EP3019153B1 (fr) 2013-07-11 2018-09-05 Chiesi Farmaceutici S.p.A. Formulation de poudre sèche comprenant un anticholinergique, un corticostéroïde et un béta-adrénergique pour l'administration par inhalation

Also Published As

Publication number Publication date
BR112018009807A8 (pt) 2019-02-26
KR20180082443A (ko) 2018-07-18
MX2018005977A (es) 2018-08-29
LT3628331T (lt) 2021-11-10
ZA201803168B (en) 2019-07-31
MA50488A (fr) 2021-05-19
US10772896B2 (en) 2020-09-15
ES2783855T3 (es) 2020-09-18
CA3005290A1 (fr) 2017-05-26
PH12018501022A1 (en) 2018-12-17
DK3377108T3 (da) 2020-04-20
HUE056260T2 (hu) 2022-02-28
PL3620176T3 (pl) 2021-11-22
PL3628331T3 (pl) 2021-11-08
SI3628331T1 (sl) 2021-11-30
EP3620176A1 (fr) 2020-03-11
ME03778B (fr) 2021-04-20
BR112018009807A2 (pt) 2018-11-06
SI3620176T1 (sl) 2021-11-30
CY1123042T1 (el) 2021-10-29
PT3377108T (pt) 2020-04-08
PH12018501022B1 (en) 2018-12-17
CN108289962A (zh) 2018-07-17
MA50487B1 (fr) 2021-09-30
US20180360849A1 (en) 2018-12-20
UA125019C2 (uk) 2021-12-29
EA037716B1 (ru) 2021-05-13
JP2019501876A (ja) 2019-01-24
US20200368252A1 (en) 2020-11-26
HUE049751T2 (hu) 2020-10-28
TWI731891B (zh) 2021-07-01
EP3628331A1 (fr) 2020-04-01
DK3628331T3 (da) 2021-09-27
MA50487A (fr) 2021-04-28
EA201890966A1 (ru) 2018-11-30
US11628175B2 (en) 2023-04-18
MA50488B1 (fr) 2021-09-30
ES2891073T3 (es) 2022-01-26
JP6963548B2 (ja) 2021-11-10
CL2018001298A1 (es) 2018-09-14
AU2016356858A1 (en) 2018-05-31
IL259329B (en) 2020-10-29
PL3377108T3 (pl) 2020-09-07
EP3377108B1 (fr) 2020-02-19
EP3620176B1 (fr) 2021-08-11
US10086004B2 (en) 2018-10-02
RS62404B1 (sr) 2021-10-29
RS60171B1 (sr) 2020-05-29
CY1124475T1 (el) 2022-07-22
SI3377108T1 (sl) 2020-05-29
SG10201912093YA (en) 2020-02-27
PE20181488A1 (es) 2018-09-18
US20210177866A1 (en) 2021-06-17
HRP20211600T1 (hr) 2022-01-21
AR106688A1 (es) 2018-02-07
GEP20207157B (en) 2020-10-12
LT3377108T (lt) 2020-07-10
RS62506B1 (sr) 2021-11-30
EP3377108A1 (fr) 2018-09-26
PT3620176T (pt) 2021-09-28
LT3620176T (lt) 2021-11-10
MD3620176T2 (ro) 2021-12-31
MA43256B1 (fr) 2020-05-29
MD3377108T2 (ro) 2020-07-31
AU2016356858B2 (en) 2021-06-24
PT3628331T (pt) 2021-10-20
HRP20211598T1 (hr) 2022-01-07
CN108289962B (zh) 2021-09-14
CO2018005141A2 (es) 2018-09-28
DK3620176T3 (da) 2021-09-20
WO2017085004A1 (fr) 2017-05-26
CY1124490T1 (el) 2022-07-22
US20170136035A1 (en) 2017-05-18
SA518391570B1 (ar) 2022-03-27
ES2895687T3 (es) 2022-02-22
HRP20200537T1 (hr) 2020-06-26
MD3628331T2 (ro) 2021-12-31
US10966991B2 (en) 2021-04-06
MA43256A (fr) 2018-09-26
HUE056441T2 (hu) 2022-02-28
IL259329A (en) 2018-07-31
TW201722404A (zh) 2017-07-01
MY186229A (en) 2021-06-30
EP3628331B1 (fr) 2021-08-11

Similar Documents

Publication Publication Date Title
SG11201804050QA (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
SG11201804048WA (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
SG11201903331QA (en) Restimulation of cryopreserved tumor infiltrating lymphocytes
SG11201805645QA (en) Lsd1 inhibitors
SG11201805072PA (en) Nicotine powder delivery system
SG11201808108XA (en) Synthesis of indazoles
SG11201408769QA (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
SG11201809751XA (en) Egfr inhibitor compounds
SG11201901558VA (en) Pth compounds with low peak-to-trough ratios
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201402986RA (en) Kinase inhibitors
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201908602UA (en) Combination therapy for the treatment of solid and hematological cancers
SG11201901438VA (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
SG11201808686VA (en) Synthesis of indazoles
SG11201903889TA (en) Crenolanib for treating flt3 mutated proliferative disorders associated mutations
SG11201900618WA (en) Permanently polarized hydroxyapatite, a process for its manufacture and uses thereof
SG11201807255YA (en) Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
SG11201900021PA (en) Methods and compositions for the treatment of cancer
SG11201809356YA (en) Multilayer coating and process of preparing the multilayer coating
SG11202000141WA (en) Powder solid dispersions comprising quercetin, process for their preparation and formulations thereof
SG11201909366XA (en) Method for preparing and analyzing fluorescent compounds in plasma
SG11201407536UA (en) Topical pharmaceutical compositions comprising terbinafine and urea
SG11201407114YA (en) Novel dosage and formulation
SG11201809671PA (en) Imidazolone compounds as human neutrophil elastase inhibitors